Europe Home Insemination Market size is estimated to achieve $2.4 billion USD by the end of 2025, and also grow at a CAGR of 6.9% during the forecast period 2021-2026.
Home insemination is a method of fertilization that contains sperm placed into the reproductive tract of the female with the help of a syringe. This method often suits single women, infertile couples, and lesbian couples. Some people are completely infertile, sub-fertile, and unexplained infertility. Most couples experience difficulties in conceiving without undergoing fertility treatment. Such people would prefer home insemination before turning to In-Vitro Fertilization (IVF) procedure. This procedure is done at home with the help of an insemination kit, which includes ovulation tests, semen containers, syringes, and other items to aid conception.
Browse for full report @ https://www.marketdataforecast.com/market-reports/europe-home-insemination-products-market
In May 2018, Glow company launched a new fertility program into the market to help millions of people to achieve their dreams of starting their family. This program offers a variety of resources for women’s health, such as fertility treatment consisting of training, funding, affordable prices, and access to world-class fertility hospitals and clinics.
In 2016, Worthington Industries, in collaboration with Intellectual Ventures, launched the innovative AIS 3 and AIS 1.5 artificial insemination shield refrigerators equipped with advanced artificial insemination shield canisters for holding samples.
In July 2019, FUJIFILM Irvine Scientific announced its new plans on constructing a new cell culture media manufacturing site in Tilburg, Netherlands. This is to accelerate development in bioproduction and cell and gene therapy markets.
Ask for a sample report @ https://www.marketdataforecast.com/market-reports/europe-home-insemination-products-market/request-sample
Market Drivers and Restraints:
The Europe home insemination market is anticipated to grow during the forecast period due to driving factors like the growing rate of infertility in the area, changing lifestyle, and growing preference of modern women on planned parenthood. Increasing support from the government through initiatives is ascribed to bolster the demand of the local market.
The factors affecting the home insemination market are mainly the strict regulations and firm laws in most of the European countries. Developing nations face the challenge of the absence of insurance coverage for fertility treatments, which further restricts the implementation of intrauterine insemination devices because of excessive out-of-pocket spending.
Europe Home Insemination Market Segmentation:
The European home insemination market has been segmented based on procedure, product type, and end-user.
The market based on procedure has been segmented into intracervical insemination, intrauterine insemination, and intratubal insemination. The intrauterine insemination sub-segment is estimated to hold the highest shares of the market. Growing awareness of the different treatment procedures for fertility is likely to boost up the demand of this segment. Intrauterine insemination is a non-invasive procedure that is expected to increase the expansion of the regional home insemination market.
The home insemination market, by product type, has been divided into home conception devices, insemination kits, and accessories. Among these, the insemination kits segment is estimated to be the fastest-growing segment in terms of value because of the growing geriatric population and is predicted to generate higher revenue during the forecast period.
The home insemination market, based on end-user, has been classified into fertility centers, hospitals and clinics, home care settings, and others. The fertility centers segment is estimated to carry the largest share of the local market during the forecast period. Further, most pharmaceutical companies are working on developing new insemination kits that possess conventional benefits. This is expected to drive the expansion of the home insemination market.
Impact of COVID-19 on Europe Home Insemination Market:
The Coronavirus pandemic has influenced the IUI devices market moderately, with limitations on elective healthcare procedures. Companies are pushed to shut down or limit production processes for non-essential applications. Due to the health risk for pregnancies amid the lockdown restrictions and crisis, the demand for IUI devices has been further impacted severely. These aspects, along with a slump in consumer expenditure, have restricted investments and thus impacted the market size. However, the market is probably going to show recovery by 2021, with steady ease of lockdown. Following government measures (particularly stay-at-home orders and social distancing norms), doctors are postponing elective surgeries (unless critical) to prevent the spread of the virus to individuals with chronic or comorbidities conditions. Further, supply chain disruptions and movement restrictions have created a logistical nightmare for market players, resulting in severe product shortages in the marketplace.
Geographically, European Home Insemination Market is divided into Germany, Russia, Great Britain, Italy, France, Spain, and Benelux countries. The market in Europe is predicted to register a significant rate of growth during the forecast period. This will be attributed to the unhealthy lifestyle and rising prevalence of infertility. Moreover, delays in pregnancy and changing lifestyles are the key factors driving the expansion of the artificial insemination market in Europe. Growing demand for Home Insemination by single mothers and lesbian couples, increasing prevalence of infertility among adults, and increasing key developments by market players have helped in the growth of the Europe Home Insemination Market infrastructure.
Some of the key players operating in the European home insemination market are Vitrolife, Pride Angel, Hi-Tech solutions, Rocket Medical plc, Invo bioscience., Genea Limited, Rinovum Women's Health, etc.